瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

待上市 12-31 12:00:00

57.970

+0.000

0.00%

最高57.970	最低57.970	成交量0.00
今开57.970	昨收57.970	日振幅0.00%
总市值93.73亿	流通市值93.73亿	总股本1.62亿
成交额0.00	换手率0.00%	流通股本1.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":57.97,"timestamp":1767153600000,"preClose":57.97,"halted":9,"volume":0,"delay":0,"floatShares":161690510,"shares":161690510,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-31 12:00:00","open":57.97,"high":57.97,"low":57.97,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767922200000},"marketStatusCode":8,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":57.97,"openAndCloseTimeList":[[1767144600000,1767153600000]],"volumeRatio":0,"ipoDetail":{"name":"瑞博生物－Ｂ","exchange":"SEHK","listingDate":"2026-01-09","sharesOutstanding":161690510,"sharesFloat":161690510,"offerAmount":27487400,"priceRange":"57.970","market":"HK","openProspectusDate":"2025-12-31","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1231/2025123100038_c.pdf","purchaseBeginDate":"2025-12-31","purchaseEndDate":"2026-01-06","winningDate":"2026-01-07","currency":"HKD","minPurchaseQuantity":200,"peRate":-32.53,"use":"1、约37.4%（或551.0百万港元）将用于核心产品RBD4059的研发；\n2、约19.6%（或288.7百万港元）将用于RBD5044的研发；\n3、约15.9%（或234.6百万港元）将用于RBD1016的研发；\n4、约10.1%（或148.7百万港元）将为研发处于临床前申报试验阶段的管线资产提供资金；\n5、约8.9%（或131.0百万港元）将分配用于推进尚未进入临床前申报试验阶段的临床前资产的开发及加强技术平台；\n6、约8.1%（或119.5百万港元）将用于营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是研究和开发小核酸药物、尤其专注于siRNA疗法的全球领军者。","subscribed":5.31,"marketCap":9373000000,"minimumCapital":11710.93,"overAllotment":true,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,500000,600000,700000,800000,900000,1000000,1374400"},"greyMarketDetail":{"greyDate":"2026-01-08","greyDateTimestamp":1767801600000,"greyOpeningTime":1767860100000,"greyClosingTime":1767868200000,"showGreyQuote":false,"openProspectusDate":"2025-12-31","listingDate":"2026-01-09"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"2600708661","title":"智通港股投资日志|1月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2600708661","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600708661?lang=zh_cn&edition=full","pubTime":"2026-01-01 00:00","pubTimestamp":1767196802,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月1日，港股上市公司投资日志如下：    类别 公司  新股活动BBSB INTL(招股中)兆易创新(招股中)红星冷链(招股中)豪威集团(招股中)MINIMAX-WP(招股中)瑞博生物-B(招股中)金浔资源(招股中)智谱(招股中)天数智芯(招股中)精锋医疗-B(招股中)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02513","02675","00100","09903","03636","06938","BK1128","03986","08610","00501","01641"],"gpt_icon":0},{"id":"1119611739","title":"新股招股｜瑞博生物-B今起招股，一手入场费11710.93港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119611739","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119611739?lang=zh_cn&edition=full","pubTime":"2025-12-31 08:56","pubTimestamp":1767142612,"startTime":"0","endTime":"0","summary":"12月31日，$瑞博生物-B$于12月31日至1月6日招股，公司拟全球发售2748.74万股H股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。申购阶梯：每手200股，入场费11710.93港元。乙组门槛为9万股，申购所需资金约526.99万港元。RBD1016通过对HBsAg的作用，旨在实现CHB的功能性治癒，同时也是一款针对CHD的差异化siRNA候选药物。基于每股股份 57.97港元的发售价并假设发售量调整权及超额配股权未获行使，估计我们将从全球发售获得所得款项净额约14.74亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜瑞博生物-B今起招股，一手入场费11710.93港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2595697745","title":"瑞博生物今起招股，获IDG、华夏基金、大成基金等基石投资认购约1亿美元，预计1月9日挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2595697745","media":"独角兽早知道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595697745?lang=zh_cn&edition=full","pubTime":"2025-12-31 07:40","pubTimestamp":1767138013,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/KI3EGORT0519VPHD.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/KI3EGORT0519VPHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["06938"],"gpt_icon":0},{"id":"2595501743","title":"瑞博生物-B(06938)于12月31日至1月6日招股，获基石投资认购约1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595501743","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595501743?lang=zh_cn&edition=full","pubTime":"2025-12-31 07:09","pubTimestamp":1767136151,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博$生物 $-B于2025年12月31日至2025年1月6日招股，公司拟全球发售2748.74万股H股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。RBD1016通过对HBsAg的作用，旨在实现CHB的功能性治愈，同时也是一款针对CHD的差异化siRNA候选药物。基于每股股份 57.97港元的发售价并假设发售量调整权及超额配股权未获行使，估计我们将从全球发售获得所得款项净额约14.74亿港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938"],"gpt_icon":0},{"id":"2594227293","title":"医药生物行业研究周报：瑞博生物通过港交所IPO聆讯 上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2594227293","media":"开源证券","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594227293?lang=zh_cn&edition=full","pubTime":"2025-12-28 00:00","pubTimestamp":1766851200,"startTime":"0","endTime":"0","summary":"瑞博生物港交所IPO 申请通过聆讯，上市在即2025 年12 月21 日，瑞博生物港交所IPO 申请通过聆讯，即将挂牌上市。瑞博生物成立于2007 年，是一家基于RNAi 技术，聚焦打造创新siRNA 技术平台的创新研发企业。成立以来，公司已搭建起肝靶向递送的RiboGalSTAR 技术平台、非肝靶向的RiboPepSTAR 技术平台、肿瘤靶向的RiboOncoSTAR 技术平台，治疗领域上覆盖了心血管、代谢和肝脏、肾脏等慢性疾病以及肿瘤领域。本周医药生物下跌0.18%，跑输沪深300 指数2.13pct，在31 个子行业中排名第25 位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228202635a4821f55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228202635a4821f55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2328871848.SGD","LU2097828805.USD","BK1589","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","LU2097828631.EUR","BK1583","LU0502904849.HKD","LU2242644610.SGD","06938","LU2097828557.USD","LU0455707207.USD","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2593061381","title":"瑞博生物港股IPO过聆讯，全球首创小核酸管线突围，获药企巨头背书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593061381","media":"和讯网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593061381?lang=zh_cn&edition=full","pubTime":"2025-12-22 13:36","pubTimestamp":1766381767,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/KHCT9VMS0519D4UH.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/KHCT9VMS0519D4UH.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["06938"],"gpt_icon":0},{"id":"2593174719","title":"瑞博生物通过聆讯：强大技术壁垒叠加专而精管线，港市再迎稀缺创新药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2593174719","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593174719?lang=zh_cn&edition=full","pubTime":"2025-12-22 09:24","pubTimestamp":1766366640,"startTime":"0","endTime":"0","summary":"随着中国小核酸药物主要开拓者——瑞博生物通过港交所聆讯，港股市场又增添了一家极具稀缺价值的创新药标的。12月21日，据港交所官网披露，苏州瑞博生物技术股份有限公司(以下简称\"瑞博生物 ...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673389083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["06938"],"gpt_icon":0},{"id":"2593276791","title":"瑞博生物通过聆讯：强大技术壁垒叠加专而精管线，港市再迎稀缺创新药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2593276791","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593276791?lang=zh_cn&edition=full","pubTime":"2025-12-21 22:25","pubTimestamp":1766327159,"startTime":"0","endTime":"0","summary":"随着中国小核酸药物主要开拓者——瑞博生物通过港交所聆讯，港股市场又增添了一家极具稀缺价值的创新药标的。故此，国内如瑞博生物这样能够突破行业技术壁垒并接近商业化前夕的创新药企可谓凤毛麟角。据悉，瑞博生物是全球为数不多拥有自主研发且经过临床验证的GalNAc递送技术的企业之一，该技术基于对siRNA药物特异性递送，增强了疗效和改善了安全性，正在颠覆创新药物的治疗理念。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06938","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2593107673","title":"瑞博生物通过聆讯：上半年营收1亿亏近亿 刚完成1.5亿融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107673","media":"雷递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107673?lang=zh_cn&edition=full","pubTime":"2025-12-21 20:41","pubTimestamp":1766320860,"startTime":"0","endTime":"0","summary":"雷递网 雷建平 12月21日瑞博生物日前通过上市聆讯，准备在港交所上市。瑞博生物2025年上半年营收1亿，亏损近亿元。瑞博生物2025年上半年营收为1.04亿元，较上年同期的6631万元增长57.6%；期内亏损为9777万元，上年同期的期内亏损为1.42亿元。截至2025年6月30日，瑞博生物持有的现金及现金等价物为3.58亿元。瑞博生物2022年9月完成E1轮融资，募资2.54亿元。瑞博生物2025年6月又进行了一轮募资，募资总额为1.52亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s/BgYIdReuw1z2A7iqa4Md3A","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2581191387","title":"瑞博生物，港股“输血”","url":"https://stock-news.laohu8.com/highlight/detail?id=2581191387","media":"TMTPost","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581191387?lang=zh_cn&edition=full","pubTime":"2025-11-05 12:39","pubTimestamp":1762317577,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tmtpost.com/7749116.html?rss=laohu8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2580822162","title":"两年亏损逾7亿，瑞博生物港股IPO“续命”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580822162","media":"凤凰网港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580822162?lang=zh_cn&edition=full","pubTime":"2025-11-02 19:49","pubTimestamp":1762084140,"startTime":"0","endTime":"0","summary":"01两年累计亏损7亿元2007年成立的瑞博生物，专注于RNA干扰技术开发及小核酸药物产业化。2023年，瑞博生物营收仅有4.4万元，2024年跃升至1.43亿元。从资金链来看，瑞博生物也面临着一定压力。在招股书中，瑞博生物表示，预计未来仍需大量资金支持研发活动及日常运营。细究研发投入策略，瑞博生物的资源配置效率也同样令人担忧。成立十八年，瑞博生物至今没有建立自主生产基地，临床样品生产完全依赖外包。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU5ODU1Mjg5Nw==&mid=2247812452&idx=1&sn=effe0d6bc98641f58f5c4ec8cd43f915&chksm=ffdb7304a58de05fdc59ad8910a9b46576f12ea6ad27d6834c52a0eb412e925dea21afb2e65f&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2579046605","title":"两年亏损逾7亿，瑞博生物港股IPO“续命”","url":"https://stock-news.laohu8.com/highlight/detail?id=2579046605","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579046605?lang=zh_cn&edition=full","pubTime":"2025-10-31 19:51","pubTimestamp":1761911493,"startTime":"0","endTime":"0","summary":"01 两年累计亏损7亿元2007年成立的瑞博生物，专注于RNA干扰技术开发及小核酸药物产业化。2023年，瑞博生物营收仅有4.4万元，2024年跃升至1.43亿元。从资金链来看，瑞博生物也面临着一定压力。在招股书中，瑞博生物表示，预计未来仍需大量资金支持研发活动及日常运营。细究研发投入策略，瑞博生物的资源配置效率也同样令人担忧。成立十八年，瑞博生物至今没有建立自主生产基地，临床样品生产完全依赖外包。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8nuDDsE9bYn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2579814485","title":"透视瑞博生物赴港之旅：管线布局均衡丰富，具备“中国版Alnylam”稀缺特质","url":"https://stock-news.laohu8.com/highlight/detail?id=2579814485","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579814485?lang=zh_cn&edition=full","pubTime":"2025-10-31 09:08","pubTimestamp":1761872935,"startTime":"0","endTime":"0","summary":"管线布局均衡丰富，核心产品“高价值”释放在即2024年5月31日，全球RNAi疗法龙头Alnylam市值正式超越Moderna，彼时Alnylam的市值约为550亿美元，而Moderna的市值则跌至约530亿美元。从整体布局特点来看，瑞博生物产品管线布局丰富且均衡，核心产品管线主要聚焦在心血管、代谢及肾脏疾病这一类大病种、大市场,商业天花板极高。据悉，2023年12月以来，瑞博生物先后与齐鲁制药、勃林格殷格翰签订合作及许可协议。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","06938","BK4588","BK4081","HDV"],"gpt_icon":0},{"id":"2579162134","title":"瑞博生物冲刺港股：上半年营收1亿亏近亿 刚完成1.5亿融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2579162134","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579162134?lang=zh_cn&edition=full","pubTime":"2025-10-30 13:45","pubTimestamp":1761803126,"startTime":"0","endTime":"0","summary":"瑞博生物日前更新招股书，准备在港交所上市。招股书显示，瑞博生物2023年、2024年营收分别为4.4万元、1.43亿元；毛利分别为2万元、1.31亿元；","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251030/6389742872292155816559935.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251030/6389742872292155816559935.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31620/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["06938"],"gpt_icon":0},{"id":"2577759511","title":"瑞博生物治疗丁型肝炎病毒感染的小核酸药物RBD1016获EMA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2577759511","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577759511?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:44","pubTimestamp":1761295484,"startTime":"0","endTime":"0","summary":"EMA的孤儿药资格认定旨在鼓励在欧盟发病率低于万分之五、导致严重威胁生命或慢性衰竭性罕见病的在研疗法。瑞博生物自主研发的RiboGalSTARTM肝靶向递送平台的安全性、有效性和长效性已通过多项临床研究得以验证，其中包括用于治疗HDV适应症的RBD1016，目前该药物正在全球同步推进乙肝和丁肝的II期临床试验。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物治疗丁型肝炎病毒感染的小核酸药物RBD1016获EMA孤儿药资格认定","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","06938"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.2777},{"period":"ytd","weight":0.2777}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司(瑞博生物)成立于2007年,公司专注于小核酸创新技术和小核酸药物研究开发,以让中国小核酸药物服务世界为愿景,研究和开发临床未被满足需求的创新药物。公司是一家致力于开发小核酸药物的创新型药物研发企业,是中国小核酸技术和小核酸制药的主要开拓者和领军者。公司主要产品有SR062—全新双重作用机制、长效降糖的小核酸药物、SR063——首款治疗AR-V7阳性前列腺癌患者药物、SR061——填补视神经损伤类疾病治疗市场空白、SR016——有望实现慢性乙肝的功能性治愈等。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}